• Autonomix Medical won a European patent for systems that assess neural activity in the eye to gauge autonomic nervous system function.
• The patent strengthens the company’s intellectual property position in Europe for its precision neuromodulation platform.
• Protection covers ocular-based monitoring methods intended to support patient assessment, treatment guidance, and procedural feedback.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240830PRIMZONEFULLFEED9833323) on September 24, 2026, and is solely responsible for the information contained therein.